Influence of perindopril combining spironolactone on neuroendocrine in treatment of chronic heart failure
XIONG Feng
WANG Hai-rong
DING Jin-ye
Abstract：Objective To observe the influence of perindopril combining spironolactone on neuroendocrine and curative effect and safety in treatment of chronic heart failure (CHF).Methods CHF patients (n=40, male 22 and female 18) were chosen from Jan. 2013 to Oct. 2014, and divided, according to ejection fraction (EF), into EF-decrease group and EF-normal group (eachn=20). Besides of standardized treatment, 2 groups were given perindopril combining spironolactone for 4 w. The changes of N-terminal pro brain natriuretic peptide (NT-proBNP), renin, angiotensin Ⅱ (AngⅡ), aldosterone (ALD) and LVEF were compared, and safety was recorded in 2 groups before and after treatment.Results The comparison in age, sex, body mass and NYHA class had no statistical difference between 2 groups (all P>0.05). The levels of NT-proBNP, renin and Ang Ⅱ decreased and LVEF increased in EF-decrease group after treatment (all P<0.05). Compared with EF-normal group, NT-proBNP increased [(457.87±103.23) pg/ml vs. (785.76±73.45) pg/ml], renin decreased [(17.92±5.37) ng(ml·h)vs. (9.81±6.94) ng(ml·h)], AngⅡdecreased [(78.28±18.89) pg/mlvs. (63.28±20.31) pg/ml] and LVEF decreased [(65.15±3.54) %vs. (56.51±7.42)%] decreased in EF-decrease group (all P<0.05).Conclusion Perindopril combining spironolactone can effectively improve the levels of renin and Ang Ⅱ with higher safety in CHF patients with decreased EF.
Keywords：Chronic heart failureSpironolactonePerindoprilNeuroendocrine system
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 97-99 )